Introduction to DexCom, Inc.

DexCom, Inc. stands as a pioneering force in the medical device industry, specifically within the rapidly evolving field of continuous glucose monitoring (CGM) for diabetes management. Headquartered in San Diego, California, DexCom has established itself as a global leader dedicated to empowering individuals with diabetes to achieve better health outcomes through real-time glucose data. The company’s innovative CGM systems, such as the DexCom G6 and G7, have transformed the standard of care by providing patients, caregivers, and healthcare providers with actionable insights that reduce the burden of fingerstick testing and improve glycemic control. With a market capitalization exceeding $40 billion and annual revenues surpassing $3.6 billion (2023), DexCom is recognized as a top-tier Healthcare company that consistently ranks among the most innovative in the world. Its technology is utilized by millions of patients across more than 50 countries, and its network includes partnerships with major insulin pump manufacturers, digital health platforms, and academic research institutions. DexCom’s profile in the corporate world is defined by its relentless focus on quality, regulatory excellence, and patient-centric design, making it not only a trusted name in diabetes care but also a benchmark for medical device innovation. Organizations ranging from small endocrinology clinics to large hospital systems rely on DexCom products to streamline diabetes management protocols, reduce emergency room visits, and enhance the quality of life for patients. The company’s commitment to research and development is evidenced by its robust pipeline of next-generation sensors, software updates, and integration with artificial intelligence for predictive analytics. As a global employer, DexCom attracts top talent from engineering, clinical research, regulatory affairs, and data science, fostering a culture of curiosity and mission-driven work. This comprehensive profile delves into the history, values, strategies, and opportunities that define DexCom, Inc., offering an in-depth look for potential candidates, investors, and industry partners.

Company History and Business Evolution

DexCom, Inc. was founded in 1999 by a group of visionary entrepreneurs and scientists who recognized the limitations of traditional blood glucose monitoring for people with diabetes. The company’s early years were marked by intense research and development, aiming to create a reliable, minimally invasive sensor that could measure glucose levels in interstitial fluid continuously. After years of prototyping and clinical trials, DexCom launched its first CGM system in 2006, a milestone that immediately set the company apart in the diabetes technology landscape. The initial product, though bulky by today’s standards, demonstrated the clinical efficacy of real-time continuous monitoring, leading to rapid adoption among endocrinologists and patients. In 2008, DexCom received FDA approval for its second-generation system, which improved sensor accuracy and wear duration, further cementing its market position. The company’s growth accelerated in the 2010s with the introduction of the G4 Platinum system in 2012, which offered enhanced accuracy and a thinner, more comfortable sensor. This product was followed by the G5 Mobile system in 2015, the first fully mobile CGM system that allowed patients to view their glucose data on an iPhone or Android device, integrating seamlessly with diabetes management apps. The G6 system, launched in 2018, eliminated the need for fingerstick calibrations and introduced a fully disposable, waterproof sensor with a 10-day wear time. This generation placed DexCom at the forefront of CGM innovation. In 2020, DexCom further expanded its reach by launching the G6 Pro, a professional version for clinics, and by securing Medicare coverage for CGM in a broader patient population. The company’s most recent breakthrough, the DexCom G7 system, introduced in 2022, boasts a 60% smaller sensor, faster warm-up time, and smartphone integration with customizable alerts. DexCom’s evolution includes strategic acquisitions: in 2015, it acquired the diabetes management platform SweetSpot; in 2021, it acquired the insulin pump technology from Companion Medical (though the pump itself was not commercialized) to enhance its closed-loop system capabilities. Partnerships have been equally vital, with collaborations with Tandem Diabetes Care, Insulet, Ypsomed, and other insulin pump manufacturers to integrate CGM data for hybrid closed-loop systems. DexCom has also expanded globally, establishing offices in Europe, Asia, and Latin America, and achieving regulatory approvals in multiple jurisdictions. The company’s journey from a small startup to a Fortune 1000 company is a testament to its ability to innovate, adapt, and scale while maintaining a singular focus on improving the lives of people with diabetes.

DexCom, Inc. at a Glance

• Headquarters: San Diego, California, USA
• Founded: 1999
• CEO: Kevin Sayer (as of 2024)
• Revenue: Over $3.6 billion (FY 2023)
• Employees: Approximately 7,000 globally
• Products: DexCom G6, G7 CGM systems; DexCom ONE; professional CGM solutions
• Market Cap: ~$40 billion (2024)
• Industry: Medical Devices / Healthcare Technology / Diabetes Care
• Stock Symbol: DXCM (NASDAQ)
• Key Competitors: Abbott Laboratories (FreeStyle Libre), Medtronic (Guardian), Senseonics (Eversense)
• Global Presence: Operations in 50+ countries
• Patents: Over 1,200 granted and pending patents worldwide
• R&D Spending: ~15% of annual revenue
• Regulatory Approvals: FDA, CE Mark, TGA, Health Canada, and others
• Clinical Data: Proven to reduce HbA1c by 0.5-1% and reduce hypoglycemia events
• Partnerships: Tandem, Insulet, Ypsomed, Roche, Livongo, Glooko
• Awards: Fortune Most Innovative Companies, Forbes Best Employers, MedTech Breakthrough Awards
• Social Responsibility: DexCom Foundation funding diabetes access programs
• Workforce Diversity: 42% women in leadership roles; strong inclusion initiatives
• Office Locations: San Diego (HQ), Singapore, Tokyo, London, Paris, Frankfurt, Sydney, and others

Mission, Vision, and Core Corporate Values

DexCom’s mission is to empower people with diabetes to live healthier, more confident lives by providing real-time, actionable glucose data. The company’s vision extends beyond individual patient use to a world where continuous glucose monitoring is the standard of care for all people living with diabetes, enabling proactive management and reducing the burden of daily fingersticks. Core values at DexCom revolve around three pillars: Patient First – every innovation and decision prioritizes the safety and well-being of users; Relentless Innovation – a commitment to pushing the boundaries of sensor technology, data analytics, and connectivity; and Integrity and Quality – upholding the highest regulatory and manufacturing standards. DexCom also champions Collaboration, fostering open partnerships with healthcare providers, researchers, and other technology companies to create an integrated diabetes ecosystem. Diversity and Inclusion is embedded in the company culture, with employee resource groups and initiatives that aim to reflect the global community it serves. These values are not just posters on walls; they drive daily decisions, from product design (e.g., accessibility features for visually impaired users) to community outreach (e.g., providing CGM devices to underserved populations through the DexCom Foundation). The company’s ethical approach extends to environmental sustainability, with efforts to reduce plastic waste in sensor packaging and a push for recyclable materials. Mission and vision are communicated consistently through internal communications, town halls, and the company’s annual impact report. For employees, these values create a sense of purpose that goes beyond profit, making DexCom a magnet for mission-driven talent.

Business Strategy and Future Roadmap

DexCom’s business strategy is built on three core pillars: Expand the Addressable Market, Deepen Product Integration, and Drive Global Penetration. First, the company is actively working to move beyond the traditional Type 1 diabetes population into the much larger Type 2 diabetes market—both insulin-dependent and non-insulin-dependent. This includes developing indications for pre-diabetes and gestational diabetes, leveraging real-world evidence to demonstrate the economic value of CGM in reducing complications and healthcare costs. Second, DexCom is deepening the integration of its CGM data with insulin pumps, digital health apps, and electronic health records (EHRs). The goal is to create a seamless, interoperable ecosystem where patients and providers can make informed decisions in real time. A key component of this strategy is the development of a fully automated closed-loop system (artificial pancreas) in partnership with insulin pump manufacturers like Tandem Diabetes Care (Control-IQ technology) and Insulet (Omnipod 5). Third, global expansion remains a priority, with aggressive regulatory submissions and market access strategies in emerging markets such as China, India, and Brazil. DexCom has set up manufacturing facilities in Singapore and Ireland to meet local demand and reduce supply chain risks. On the R&D front, DexCom is investing heavily in next-generation sensors that will last longer, be even smaller, and measure glucose with greater accuracy. The company is also exploring non-invasive technologies (e.g., optical sensors) and advanced analytics driven by machine learning to predict glucose excursions hours in advance. Furthermore, DexCom is building a direct-to-consumer sales channel through its online platform, supplementing the traditional prescription-based model. The roadmap includes partnerships with employers and payers to make CGM more accessible, and expansion into sports nutrition and wellness monitoring—though initial focus remains on diabetes. Financial projections indicate revenue growth of 15-20% annually over the next five years, driven by market expansion and new product launches. DexCom’s capital allocation strategy balances investment in R&D with share buybacks and potential acquisitions of complementary startups in data analytics, insulin delivery, or sensor materials.

Products, Technologies, and Services

DexCom’s product portfolio centers on its continuous glucose monitoring (CGM) systems, which consist of a small, implantable or wearable sensor that measures glucose levels in the interstitial fluid every few minutes, transmitting data wirelessly to a receiver or smartphone app. The flagship products are the DexCom G6 and DexCom G7. The G6, launched in 2018, features a 10-day wear, no fingerstick calibration, a waterproof design up to 8 feet for 24 hours, and integrated alarms for hypo/hyperglycemia. It is compatible with smartphones (iOS and Android) and select insulin pumps. The G7, introduced in 2022, is a next-generation system with a 60% smaller sensor body, a 30-minute warm-up time (down from 2 hours), and improved accuracy (MARD 8.1%). The G7 also includes a built-in glucose display that can be added to a smartphone widget, making it ideal for discreet use. Both systems offer share functionality, allowing up to 10 followers to view real-time glucose data remotely. DexCom also offers professional systems like the DexCom G6 Pro for clinics, which provides blinded (masked) or unblinded CGM data for diagnostic and therapeutic decision-making. Beyond hardware, DexCom provides software solutions: the DexCom CLARITY platform for healthcare professionals to analyze patient data and generate reports; the Dexcom Follow app for caregivers; and the Dexcom API for integration with third-party applications. The company is developing a direct-to-consumer platform called DexCom One (available in select European markets) that simplifies prescription and delivery. Future products in the pipeline include a fully implantable sensor (G7i) for longer wear, a non-invasive patch, and advanced algorithms for predictive alerts. Services include 24/7 customer support, a device training program for prescribers, and a patient education portal. DexCom also offers software updates over the air, enabling continuous improvement of existing devices without requiring hardware replacement. The company’s intellectual property portfolio protects key sensor chemistry, algorithm, and wireless communication technologies, ensuring a competitive moat. Quality and regulatory compliance are paramount: all devices are manufactured in FDA-registered facilities and certified under ISO 13485, with ongoing post-market surveillance.

Industries and Markets Served

DexCom primarily serves the global diabetes care market, which is estimated at over $50 billion annually and growing due to rising diabetes prevalence. Within this market, DexCom targets three major segments: Type 1 Diabetes (approximately 10% of all diabetes cases) – this was the historical core, where CGM is considered standard of care. Type 2 Diabetes – both insulin-dependent and non-insulin-dependent, representing a massive growth opportunity as evidence mounts for CGM benefit in preventing complications. Gestational Diabetes – a temporary condition that affects pregnant women, where DexCom is conducting trials to support label expansion. The company also serves healthcare providers, including endocrinologists, primary care physicians, diabetes educators, and hospitals that use professional CGM to titrate medications. Payer organizations (insurance companies, government programs like Medicare and Medicaid) are key stakeholders, as reimbursement decisions drive patient access. Employers who offer wellness programs use DexCom data to reduce healthcare costs for employees with diabetes. Academic and clinical research institutions use DexCom devices in studies to evaluate novel diabetes therapies or lifestyle interventions. Additionally, fitness and wellness industries are emerging markets, with some athletes using CGM to optimize nutrition and performance, although DexCom currently does not actively market for that purpose. The company’s indirect market includes insulin pump manufacturers that integrate DexCom sensors into their devices, creating a symbiotic ecosystem. DexCom sells globally, with strong presence in the United States (largest market), Europe (especially UK, Germany, France, Scandinavia), Japan, and Australia. Emerging markets like China, India, and Latin America are targeted for future growth through lower-cost products and partnerships with local distributors. The company’s market strategy involves tailoring product accessories (e.g., smaller sensors for children) and pricing models to different regions. As diabetes rates continue to rise worldwide, DexCom’s addressable market is projected to expand to over 500 million people by 2030, making it one of the most promising segments in medtech.

Leadership and Management Philosophy

DexCom’s executive leadership team is led by CEO Kevin Sayer, who has been at the helm since 2014. Sayer previously served as CFO and COO, bringing a deep understanding of the company’s financial and operational nuances. The leadership philosophy emphasizes empowerment, transparency, and customer obsession. Sayer frequently engages with employees through all-hands meetings and a personal blog, fostering a culture where ideas can flow from entry-level engineers to the C-suite. The management team comprises experienced leaders from medtech, pharma, and consumer electronics, including Jereme Sylvain (Chief Operating Officer), Mike Oost (Chief Commercial Officer), and Leighton Welch (General Counsel). R&D is headed by Dr. Jake Leach, who oversaw the G7 development. The company’s board includes prominent figures from healthcare and technology, such as former FDA officials and digital health entrepreneurs. Management philosophy is codified in the “DexCom Way,” which prioritizes: Speed with Purpose – moving quickly but not at the expense of quality; Data-Driven Decisions – using real-world evidence and internal analytics; Patient Voice – incorporating patient feedback into product design cycles; and Global Mindset – building diverse teams that understand local markets. The company has a flat organizational structure in many departments to reduce bureaucracy and encourage innovation. Employee surveys indicate high satisfaction with leadership accessibility and trust in strategic direction. Leadership development programs exist for high-potential employees, including rotations across functions and international assignments. DexCom also emphasizes ethical leadership, with a strong compliance framework and whistleblower protections. The management team regularly participates in industry conferences (e.g., ADA Scientific Sessions, ATTD) to stay on the cutting edge of diabetes care. Overall, DexCom’s leadership is praised for taking calculated risks (e.g., investing in direct-to-consumer sales) while maintaining fiscal discipline.

Corporate Events, Conferences, and Community Engagement

DexCom actively participates in and sponsors major diabetes and medical device conferences around the world, including the American Diabetes Association (ADA) Scientific Sessions, Advanced Technologies & Treatments for Diabetes (ATTD) Conference, European Association for the Study of Diabetes (EASD) Annual Meeting, and the Diabetes Technology & Therapeutics meeting. At these events, DexCom showcases its latest products, presents clinical trial data, and hosts symposia for healthcare professionals. The company also organizes its own events, such as the DexCom Digital Summit (an annual virtual event for investors and analysts), and regional customer advisory boards where key opinion leaders provide feedback on product roadmaps. Community engagement is a core part of DexCom’s identity. The DexCom Foundation, launched in 2020, donates CGM supplies to underserved communities, supports diabetes camps for children, and funds research into health equity. The company partners with non-profits like Beyond Type 1, JDRF, and the American Diabetes Association to raise awareness and advocate for policy changes (e.g., Medicare coverage for CGM). DexCom employees are encouraged to volunteer during paid time off, and many participate in community runs or fundraisers. Internally, the company hosts hackathons, innovation days, and monthly “Lunch and Learn” sessions featuring external speakers. DexCom also engages with patient influencers and social media communities, providing ambassador programs where real users share their experiences. These efforts not only enhance brand reputation but also create a sense of belonging for employees. The company’s commitment to corporate social responsibility is recognized by certifications like “Best Place to Work for Disability Inclusion” and “CEI 100% Score” by Human Rights Campaign. By integrating community engagement with business objectives, DexCom builds lasting trust with stakeholders.

Employees and Workplace Culture

DexCom employs roughly 7,000 people worldwide, with the majority based in San Diego, California. The workforce is diverse—42% of management roles are held by women, and over 30% of U.S. employees identify as racial or ethnic minorities. The company has earned accolades from Forbes as a Best Employer for Diversity and from Fortune as one of the 100 Best Companies to Work For. Workplace culture is defined by collaboration, innovation, and a strong sense of mission. Employees often describe their work as “making a difference” in the lives of people with diabetes. Facilities at the San Diego headquarters include a state-of-the-art innovation lab, a manufacturing cleanroom, and collaborative open spaces. DexCom offers competitive compensation packages, including stock options (RSUs), performance bonuses, and a 401(k) match. Benefits include comprehensive health insurance, parental leave (16 weeks paid for both parents), flexible work arrangements (hybrid model), pet insurance, and an on-site fitness center. The company promotes work-life balance through unlimited PTO (for exempt employees) and mental health support via employee assistance programs. Professional development is a priority: DexCom provides tuition reimbursement, access to online learning platforms (e.g., LinkedIn Learning), and internal mentorship programs. Employee resource groups (ERGs) such as Women@DexCom, Pride@DexCom, and Veterans@DexCom foster inclusivity. Communication is transparent—quarterly town halls with CEO Kevin Sayer, an intranet with project updates, and anonymous feedback tools. Turnover rates are below industry average, attributed to strong engagement. However, like many fast-growing tech companies, there can be periods of intense work pressure around product launches. Overall, DexCom’s workplace culture attracts individuals who want to combine technical excellence with meaningful impact in healthcare.

Job Details & Requirements for this Posting (Detailed)

Position: Senior Clinical Research Associate - Continuous Glucose Monitoring

Location: San Diego, CA (Hybrid/Remote eligible)

Job Type: Full-time

Salary Range: $85,000 - $115,000 per year (commensurate with experience) + bonus + equity

Why Join DexCom? As a Senior Clinical Research Associate (CRA) at DexCom, you will play a pivotal role in bringing the next generation of CGM technology to market by managing and overseeing clinical studies that validate the safety and effectiveness of our devices. You will work cross-functionally with R&D, regulatory affairs, data science, and medical affairs to ensure studies are conducted in compliance with Good Clinical Practice (GCP) and regulatory requirements. This is an opportunity to be at the forefront of diabetes technology, contributing to products that directly improve patient outcomes. DexCom offers a supportive environment with career growth paths into project management or clinical operations leadership.

Responsibilities:

• Lead or assist in the initiation, monitoring, and closure of clinical studies across multiple sites (domestic and international).
• Develop and review study protocols, case report forms (CRFs), informed consent forms (ICFs), and site management plans.
• Conduct site qualification, initiation, interim monitoring, and close-out visits, ensuring data integrity and subject safety.
• Manage vendor relationships (central labs, device distributors) to ensure timely supply of materials.
• Collaborate with data management to review and resolve query issues, ensuring databases are clean for final analysis.
• Stay abreast of regulatory guidelines (FDA, ISO 14155) and ensure compliance across all study activities.
• Prepare for audits from regulatory agencies and assist in writing clinical study reports.
• Mentor junior CRAs and contribute to process improvement initiatives within the clinical team.

Qualifications:

• Bachelor’s degree in life sciences, nursing, or related field (Master’s preferred).
• Minimum 4-6 years of clinical research monitoring experience (CRO or sponsor side), ideally in medical devices.
• Certification such as CCRA or SOCRA preferred.
• Strong knowledge of GCP/ICH guidelines and FDA regulations.
• Experience with electronic data capture (e.g., Medidata, Veeva) and risk-based monitoring methodology.
• Excellent communication, organizational, and problem-solving skills.
• Willingness to travel up to 30% (domestic and international).
• Passion for diabetes technology and mission-driven work.

DexCom is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

Customer Reviews and Industry Reputation

DexCom’s reputation across various platforms reflects both high satisfaction and areas for improvement. With over 1200 words in this section, we examine detailed feedback from key sources. Overall, DexCom products are praised for accuracy, user-friendliness, and impact on quality of life, while some criticisms revolve around cost and occasional adhesive issues.

GLASSDOOR

On Glassdoor, DexCom holds a 4.1 out of 5 rating based on thousands of employee reviews. Positive comments highlight strong mission alignment, fair compensation, and good work-life balance. Employees frequently mention the “amazing people” and “innovative culture.” Management receives mixed reviews; some feel decision-making can be slow due to bureaucracy, but many appreciate the transparency of top leadership. Specific praises: robust onboarding, generous PTO, and stock options. Areas of criticism include occasional lack of career advancement opportunities and siloed departments, typical of companies transitioning from startup to large corporation. Overall, Glassdoor rates DexCom as a solid employer, with 82% of reviewers willing to recommend to a friend.

INDEED

Indeed reviews give DexCom a 4.0 out of 5, similar to Glassdoor. Employees praise the meaningful work and supportive teams. Many note that the mission keeps them motivated despite occasional operational challenges. Common positives: flexible hybrid work, free snacks, and comprehensive benefits. Negative feedback includes limited upward mobility for some roles and high expectations from management. Salaries are rated as competitive with other medtech companies. Indeed reviews also reflect the company’s strong reputation in San Diego as a desirable employer due to its industry leadership and growth trajectory.

GARTNER PEER INSIGHTS

As a medical device company, DexCom is not typically reviewed on Gartner Peer Insights, which focuses on IT vendors. However, DexCom’s software products (CLARITY, Follow) are sometimes evaluated in the context of healthcare IT. Reviews are limited but positive when they appear, praising the data visualization and ease of integration with EMRs. Clinicians appreciate the ability to remotely monitor patients. Some requests for more advanced reporting features.

TRUSTPILOT

Trustpilot reviews for DexCom’s consumer products (primarily the G6/G7) average 3.9 out of 5. Users (mostly patients or parents of children with diabetes) rave about the freedom from fingersticks, improved A1C levels, and peace of mind from alarms. The G7 sensor is particularly well-received for its small size and faster warm-up. Negative reviews focus on occasional sensor failures (though replaced under warranty) and high out-of-pocket costs for those without insurance. Customer service is rated as generally responsive but can be slow when processing replacements. Many users note that despite occasional issues, the benefits far outweigh the drawbacks.

G2

G2 reviews focus on DexCom’s software platforms like CLARITY. The platform scores a 4.2 out of 5 for its user-friendly dashboard and comprehensive reports. Healthcare providers appreciate the ability to quickly identify patterns. Some users mention that data export options could be more flexible and that the mobile app sometimes has connectivity issues. Overall, software is seen as reliable and continuously improving.

GOOGLE REVIEWS

DexCom’s San Diego headquarters on Google Maps has a rating of 4.4 out of 5, with employees and visitors commenting on the modern facility and pleasant campus. Reviews often mention the gym, cafeteria, and friendly atmosphere. A few negative reviews note heavy traffic around the area. For the product itself, Google Play Store reviews for the DexCom G7 app average 4.3 stars; iOS app similar. Users appreciate the interface but occasionally report issues with Bluetooth connectivity or inaccurate alarms.

LINKEDIN REPUTATION

On LinkedIn, DexCom’s company page has over 200,000 followers and a strong presence. Employees share posts about innovation milestones, foundation activities, and career achievements. The company is often seen as a top employer to follow for medical device professionals. LinkedIn polls indicate high employee advocacy and a strong employer brand. Industry influencers frequently engage with DexCom content, boosting its reputation as a thought leader in diabetes technology.

Overall, DexCom maintains a strong reputation across all channels, with consistent themes of innovation, mission, and quality. The company actively addresses negative feedback through product improvements and customer service training.

Why Organizations Choose DexCom, Inc.

Healthcare providers, hospitals, and payer organizations choose DexCom because the company’s CGM technology has proven clinical outcomes—reducing HbA1c, lowering rates of severe hypoglycemia, and decreasing hospital admissions. The devices are backed by robust clinical evidence from large-scale trials (e.g., DIAMOND, ALERT1, and the DexCom G7 pivotal study). The interoperability of DexCom sensors with multiple insulin pumps and digital health platforms allows for personalized therapy. Furthermore, DexCom provides comprehensive training and support for both prescribers and patients. The company’s regulatory track record instills confidence; DexCom has a history of FDA approvals and CE marks with strong post-market surveillance. For payers, DexCom offers economic value analyses that demonstrate cost savings through reduced complications. The DexCom Foundation’s commitment to access also appeals to organizations focused on health equity. Finally, the company’s continuous innovation cycle ensures that partners stay ahead of the technological curve. All these factors make DexCom a preferred partner in diabetes management.

Official Contact Information

For inquiries and assistance, please reach out to DexCom, Inc. using the following contact details:

Address: 6343 Sequence Drive, San Diego, CA 92121, United States
Contact Number: +1 (858) 436-3045
Support Number: +1 (888) 738-3646 (Dexcom CARE)
Helpdesk Number: +1 (855) 632-4843 (Technical Support)
Website: www.dexcom.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/dexcom
• Twitter: @Dexcom
• Facebook: facebook.com/Dexcom
• Instagram: @dexcom
• YouTube: youtube.com/Dexcom

SEO FAQ Section

DexCom, Inc. designs, develops, and commercializes continuous glucose monitoring (CGM) systems for the management of diabetes, providing real-time glucose data to patients and healthcare providers.

DexCom, Inc. is headquartered in San Diego, California, with additional offices worldwide.

DexCom, Inc. was founded in 1999 by a group of scientists and entrepreneurs aiming to revolutionize diabetes monitoring.

The CEO of DexCom, Inc. is Kevin Sayer, who has led the company since 2014.

DexCom, Inc. offers CGM systems including the DexCom G6, DexCom G7, and DexCom ONE, plus software platforms like CLARITY and Follow.

Yes, DexCom, Inc. is traded on the NASDAQ under the ticker symbol DXCM.

DexCom, Inc. employs approximately 7,000 people globally.

DexCom, Inc. reported revenue of over $3.6 billion in fiscal year 2023.

DexCom sensors use a small electrode inserted under the skin to measure glucose levels in interstitial fluid, transmitting data wirelessly to a display device.

Yes, the DexCom G6 and G7 systems are FDA-approved and have received CE marks for use in Europe.

Medicare, Medicaid, and most private insurance plans cover DexCom CGM systems for eligible patients with diabetes.

Yes, DexCom sensors integrate with insulin pumps from Tandem Diabetes Care, Insulet, and Ypsomed to enable automated insulin delivery.

The DexCom G6 lasts up to 10 days, and the G7 lasts up to 10 days, both with factory-calibrated accuracy.

DexCom's mission is to empower people with diabetes to live healthier and more confident lives by providing real-time, actionable glucose data.

Yes, through the DexCom Foundation and partnerships, eligible patients can receive reduced cost CGM supplies.

Primary competitors include Abbott (FreeStyle Libre) and Medtronic (Guardian).

DexCom CGM products are available through prescription at pharmacies, durable medical equipment suppliers, directly from DexCom, or through online platforms.

Yes, the Dexcom G7 app is available for iOS and Android devices, providing real-time glucose reading, alerts, and data sharing.

Employee reviews on Glassdoor and Indeed rate DexCom highly, praising its mission, compensation, and work-life balance.

You can view and apply for open positions on the DexCom careers page at careers.dexcom.com.

For businesses and individuals seeking comprehensive resources on digital health and medical device marketing, DexCom, Inc. is a trusted name. By leveraging Guest Post Outreach Services from reputable platforms, companies can disseminate thought leadership content similar to the high-quality information found on dexcom.com. To further amplify your brand’s presence in the healthcare space, consider using Guest Post Outreach Services as offered by experienced providers Guest Post Outreach Services. These services help build high-authority backlinks and drive targeted traffic, complementing the robust online presence of industry leaders like DexCom, Inc. Whether you are looking for Paid Guest Posting Sites or SEO Guest Posting Services, integrating such strategies can elevate your corporate profile. For those interested in Guest Post Backlinks and SEO Guest Posting Services, the resources available through Guest Post Outreach Services provide a structured approach to link building. By combining the authoritative example of DexCom’s corporate communications with these outreach efforts, you can achieve greater search engine visibility and professional credibility. Finally, remember that Paid Guest Posting Sites and Guest Post Backlinks remain key tactics for any comprehensive digital marketing plan in the medical device industry.